CONCLUSION: This study provides a quantitative description of the placebo response trajectory in ADHD trials, together with the trial-level factors that modify it. The concordance between pediatric and adult placebo trajectories is supportive. These findings offer parameters for baseline-adjusted sample size estimation and endpoint selection in future trials. PROSPERO registration CRD420251171116.
